-

Zai Lab Announces Participation in Investor Conferences in September 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2025:

Cantor Global Healthcare Conference
Presentation: Thursday, September 4, 2025, 10:20 a.m. ET
Location: New York, NY

Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat: Tuesday, September 9, 2025, 2:35 p.m. ET
Location: New York, NY

Live webcasts will be available on the Investor Relations page of Zai Lab’s website at ir.zailaboratory.com/webcasts-presentations and archived replays will be available for up to 90 days following the completion of the events.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.X.com/ZaiLab_Global.

Contacts

For more information, please contact:

Investor Relations:
Christine Chiou
+1 (917) 886-6929
christine.chiou1@zailaboratory.com

Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media:
Shaun Maccoun
+1 (857) 270-8854
shaun.maccoun@zailaboratory.com

Xiaoyu Chen
+86 185 0015 5011
xiaoyu.chen@zailaboratory.com

Zai Lab Limited

NASDAQ:ZLAB

Release Versions

Contacts

For more information, please contact:

Investor Relations:
Christine Chiou
+1 (917) 886-6929
christine.chiou1@zailaboratory.com

Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media:
Shaun Maccoun
+1 (857) 270-8854
shaun.maccoun@zailaboratory.com

Xiaoyu Chen
+86 185 0015 5011
xiaoyu.chen@zailaboratory.com

More News From Zai Lab Limited

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, has been selected for an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22-26, 2025, in Boston, Massachusetts. The presentation will...

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. “Today’s approval of TIVDAK marks an important milestone for Zai Lab, further strengthening our Women’s franchise in Greater China,” said Andrew Zhu, Chief Commercial Of...

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation allows Zai Lab to take advantage of an expedited approval procedure for TTFields that offers opportunit...
Back to Newsroom